Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease

This article discusses the need for biomarkers and surrogate endpoints for future clinical trials in individuals at risk for Huntington's disease. Definitions and criteria are presented for biomarkers and surrogate endpoints, and data are presented suggesting that striatal volumes, as measured on MRI scans, meet the criteria for a biomarker. Biomarkers can be used in lieu of clinical endpoints in treatment trials if there is evidence that treatment affects the biomarker in a way that is predictive of endpoint status. Because there are currently no effective treatments for Huntington's disease, it is not yet possible to validate whether change in MRI striatal volumes can serve as an effective surrogate endpoint. It is recommended that future clinical trials be designed using MRI striatal volumes to "screen" potential treatments. Those treatments that reduce the rate of striatal atrophy can then be tested with delay of symptom onset as the clinical endpoint. This strategy is essential if efficient and cost-effective clinical trials are to be conducted in the preclinical stage of Huntington's disease.

[1]  G. Pearlson,et al.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[2]  G. Pearlson,et al.  Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.

[3]  G. M. Halliday,et al.  Regional Specificity of Brain Atrophy in Huntington's Disease , 1998, Experimental Neurology.

[4]  J. Penney,et al.  Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.

[5]  S. Folstein,et al.  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. , 1995, American journal of human genetics.

[6]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[7]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[8]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[9]  A. Young,et al.  Interrater agreement in the assessment of motor manifestations of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[10]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[11]  G. Pearlson,et al.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.

[12]  J. Brandt,et al.  Onset and rate of striatal atrophy in preclinical Huntington disease , 2004, Neurology.

[13]  J. Brandt,et al.  When does Huntington's disease begin? , 1998, Journal of the International Neuropsychological Society.

[14]  C A Ross,et al.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. , 1993, Human molecular genetics.

[15]  L. Raymond,et al.  Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study , 2003, Brain Research Bulletin.